Stockscreener 앱 받기
5.30
2.51%
0.13
시간 외 거래:
5.08
-0.22
-4.15%
전일 마감가:
$5.17
열려 있는:
$5.05
하루 거래량:
219.76K
Relative Volume:
0.81
시가총액:
$325.28M
수익:
-
순이익/손실:
$-130.41M
주가수익비율:
-2.0623
EPS:
-2.57
순현금흐름:
$-67.76M
1주 성능:
-10.92%
1개월 성능:
-14.10%
6개월 성능:
-24.82%
1년 성능:
+10.65%
1일 변동 폭
$4.9202
$5.48
1주일 범위
$4.9202
$6.10
52주 변동 폭
$2.44
$8.84
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Learn to Evaluate (GLUE) using the Charts - Stock Traders Daily
Potential Price Increase for Monte Rosa Therapeutics Inc (GLUE) After Recent Insider Activity - Knox Daily
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com South Africa
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock By Investing.com - Investing.com Australia
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com India
Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com
Can you now get a good deal on Monte Rosa Therapeutics Inc’s shares? - US Post News
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth - Simply Wall St
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 9.7% in August - Defense World
Meeder Asset Management Inc. Purchases Shares of 10,050 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Versant Venture Capital Vi, L. Sells 541,897 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock - Defense World
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com Australia
Wedbush Reiterates Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Major Shareholder Versant Venture Capital Vi, L. Sells 9,269 Shares - MarketBeat
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com
Versant entities sell over $3.4 million in Monte Rosa Therapeutics stock - Investing.com India
Monte Rosa Therapeutics' (GLUE) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 3.3% - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 3.3% - Defense World
Monte Rosa Therapeutics Inc’s Banking’s 100-Day Moving Average at 4.77: Will the Stock Break Through? - The InvestChronicle
Market Insights: Monte Rosa Therapeutics Inc (GLUE)’s Notable Drop of -3.44, Closing at 6.17 - The Dwinnex
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth - Yahoo Finance
Monte Rosa begins trial of new autoimmune disease therapy - Investing.com India
Monte Rosa begins trial of new autoimmune disease therapy - Investing.com
Monte Rosa begins trial of new autoimmune disease therapy By Investing.com - Investing.com Australia
Monte Rosa begins trial of new autoimmune disease therapy By Investing.com - Investing.com UK
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - GlobeNewswire
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study - StockTitan
Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00 - Defense World
Vanguard Group Inc. Grows Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) PT Lowered to $17.00 at Wells Fargo & Company - MarketBeat
Monte Rosa Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Monte Rosa Therapeutics: Q2 Earnings Snapshot - San Francisco Chronicle
Monte Rosa Therapeutics: Q2 Earnings Snapshot - New Haven Register
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics: Q2 Earnings Snapshot - Thehour.com
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan
Price T Rowe Associates Inc. MD Has $35.93 Million Stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat
Price T Rowe Associates Inc. MD Buys 155,880 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Acadian Asset Management LLC Raises Stock Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) & Finch Therapeutics Group (NASDAQ:FNCH) - Defense World
Head to Head Comparison: TScan Therapeutics (NASDAQ:TCRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 29.3% - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Short Interest Up 29.3% in June - MarketBeat
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Increases By 29.3% - American Banking and Market News
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - Bakersfield.com
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):